Background: Emerging studies have reported the potential anticancer activity of FDA-approved benzimidazole-based anthelmintics against lung cancer. Therefore, the current systematic review aimed to explore the anticancer activity of benzimidazole-based anthelmintics in lung cancer animal models.
Method: The databases including Pubmed, ScienceDirect, and Google Scholar were searched till April 2024 for the animal studies evaluating the anticancer activity of benzimidazole-based anthelmintics against lung cancer. The relevant data was extracted in the prepared format in Microsoft Excel. Systematic Review Center for Laboratory Animal Experimentation (SYRCLE) risk of bias (RoB) was used to assess the quality of included studies. The protocol for this study has been registered in PROSPERO (Registration number: CRD42022352141).
Results: Initially, we obtained 4150 articles, and finally eight articles were included in the current study. The information in the included studies was a bit diversified including different benzimidazole-based anthelmintics, dosage, route of administration, and duration of experiments. However, all studies reported that exposure to benzimidazole-based anthelmintics decreased tumor size and tumor volume in animal models of lung cancer.
Conclusion: In conclusion, benzimidazole-based anthelmintics have the potential to treat lung cancer. However, more controlled and thorough preclinical studies are required to evaluate its efficacy, safety, and mechanism of anticancer activities.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/0115748863308476240702053700 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Potent α-glucosidase inhibitors with benzimidazole-propionitrile hybridization; synthesis, bioassay and docking study.
Future Med Chem
December 2024
Department of Chemistry, College of Science, Sultan Qaboos University, PO Box 36, Al-Khod 123, Muscat, Sultanate of Oman.
Article Synopsis
- - Diabetes is a major health issue, with 382 million people affected globally in 2013 and projections to rise to 592 million by 2035, primarily involving type 2 diabetes, characterized by insulin issues.
- - Researchers synthesized benzimidazole-based derivatives to evaluate their potential as antidiabetic agents, conducting reactions and various spectroscopy methods to confirm the structures of these compounds.
- - Out of 32 compounds tested, 24 showed promising α-glucosidase inhibition, with some compounds demonstrating better efficacy than the standard drug acarbose, indicating the need for further bioassay studies.
Benzimidazole-based small molecules as anticancer agents targeting telomeric G-quadruplex and inhibiting telomerase enzyme.
Future Med Chem
October 2024
Department of Chemistry, SRM Institute of Science & Technology, Kattankulathur, Tamil Nadu, 603203, India.
Telomeres, crucial for chromosomal integrity, have been related to aging and cancer formation, mainly through regulating G-quadruplex structures. G-quadruplexes are structural motifs that can arise as secondary structures of nucleic acids, especially in guanine-rich DNA and RNA regions. Targeting these structures by small compounds shows promise in the selective suppression of cell growth, opening up novel possibilities for anticancer treatment.
View Article and Find Full Text PDFNovel benzimidazole-based azine derivatives as potent urease inhibitors: synthesis, and approach.
Future Med Chem
December 2024
Department of Chemistry, University of Malakand, P.O. Box 18800, Dir Lower, Khyber Pakhtunkhwa, Pakistan.
In light of various biological activities of benzimidazole and azines, this study focuses on reporting novel derivatives of benzimidazole nucleus. Twenty novel azines of benzimidazole were synthesized, characterized and tested for urease inhibitory activity. All these derivatives showed excellent to good inhibition in the range of IC values 14.
View Article and Find Full Text PDFNew Family of Benzimidazole-Based Chitosan Derivatives against .
J Agric Food Chem
October 2024
Department of Pharmacy, Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, P. R. China.
is the major fungus that causes blue mold and produces patulin, threatening human health. Due to health and environmental pollution concerns, chitosan (CS) has attracted more and more attention as a safer alternative to synthetic fungicides for the control of blue mold. In the present study, four different benzimidazole groups were introduced onto CS by the acylation reaction to obtain benzimidazole-based chitosan derivatives (R1b-R4b).
View Article and Find Full Text PDFA Systematic Review of the Impact of Benzimidazole-based Anthelmintics on Lung Cancer in Animal Models.
Curr Drug Saf
July 2024
Department of Translational & Clinical Research, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi 110062, India.
Background: Emerging studies have reported the potential anticancer activity of FDA-approved benzimidazole-based anthelmintics against lung cancer. Therefore, the current systematic review aimed to explore the anticancer activity of benzimidazole-based anthelmintics in lung cancer animal models.
Method: The databases including Pubmed, ScienceDirect, and Google Scholar were searched till April 2024 for the animal studies evaluating the anticancer activity of benzimidazole-based anthelmintics against lung cancer.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!